RavenQuest Completes Non-Brokered Private Placement
20 7월 2019 - 5:05AM
RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt:
1IT) (the “
Company” or
“
RavenQuest”) announces that it has completed the
final tranche of its previously announced (June 28, 2019)
non-brokered private placement of units. In connection with
completion of the final tranche of the placement, the Company
issued an additional 907,000 units at a price of $0.50 per
unit. When combined with the first tranche, the Company has
issued an aggregate of 5,047,000 units (each, a
“
Unit”) at a price of CDN$0.50 per Unit for gross
proceeds of CDN$2,523,500 (the “
Financing”).
Each “Unit” consists of one common share of the
Company and one share purchase warrant (each, a
“Warrant”). Each Warrant entitles the holder
to purchase one additional common share of the Company at a price
of CDN$0.60 per share for a period of two (2) years.
The proceeds of the Financing will be used for
general corporate purposes. In connection with completion of
the Financing, the Company has paid finders’ fees of $162,645 and
issued 325,290 Warrants as consideration for referring subscribers
to the Financing. All securities issued in connection with
the Financing are subject to a four-month-and-one-day statutory
hold period in accordance with applicable securities laws.
For more information, access RavenQuest’s
investor presentation, fact sheet and videos here.
Follow RavenQuest on Twitter
@RQBGlobal
About RavenQuest BioMed
Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development. RavenQuest is a licensed producer with
facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with
McGill University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant.
The Company focuses on partnerships with Indigenous
communities.
On Behalf of the Board of Directors
ofRAVENQUEST BIOMED INC.
“George Robinson”Chief Executive Officer
For further information, please contact: |
Mathieu McDonald, Corporate Communications |
|
1-877-282-1586 |
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statements
All statements in this press release, other than
statements of historical fact, are "forward-looking information"
with respect to the Company within the meaning of applicable
securities laws. The Company provides forward-looking statements
for the purpose of conveying information about current expectations
and plans relating to the future and readers are cautioned that
such statements may not be appropriate for other purposes. By its
nature, this information is subject to inherent risks and
uncertainties that may be general or specific and which give rise
to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. These risks and uncertainties
include but are not limited to those identified and reported in the
Company’s public filings under the Company’s SEDAR profile at
www.sedar.com. Although the Company has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements. The
Company disclaims any intention or obligation to update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise unless required by
law.
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024